5AM Venture Management’s Entrada Therapeutics TRDA Stock Holding History

5AM Venture Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$29.9M	Hold	4,056,379	–	–	10.37%	3
2026 Q1	$51.2M	Hold	4,056,379	–	–	14.21%	2
2025 Q4	$41.7M	Sell	4,056,379 -200,000	-5%	-$1.69M	13.11%	1
2025 Q3	$24.7M	Sell	4,256,379 -52,000	-1%	-$304K	9.04%	2
2025 Q2	$29M	Sell	4,308,379 -100,000	-2%	-$805K	11.13%	2
2025 Q1	$39.9M	Hold	4,408,379	–	–	15.07%	1
2024 Q4	$76.2M	Hold	4,408,379	–	–	18.19%	1
2024 Q3	$70.4M	Hold	4,408,379	–	–	14.55%	1
2024 Q2	$62.8M	Hold	4,408,379	–	–	14.05%	2
2024 Q1	$62.5M	Hold	4,408,379	–	–	13.99%	2
2023 Q4	$66.5M	Hold	4,408,379	–	–	17.65%	2
2023 Q3	$69.7M	Hold	4,408,379	–	–	20.04%	2
2023 Q2	$66.7M	Hold	4,408,379	–	–	16.63%	2
2023 Q1	$63.9M	Hold	4,408,379	–	–	16.35%	2
2022 Q4	$59.6M	Hold	4,408,379	–	–	16.02%	2
2022 Q3	$69.5M	Hold	4,408,379	–	–	13.31%	2
2022 Q2	$53.7M	Hold	4,408,379	–	–	13.28%	2
2022 Q1	$41.4M	Hold	4,408,379	–	–	9.04%	3
2021 Q4	$75.5M	Buy	+4,408,379	New	+$107M	14.17%	2

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

5AM Venture Management's TRDA Position: Q2 2026 in Review

5AM Venture Management held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 4,056,379 shares worth $29.9M. The position accounts for 10.37% of the portfolio, ranked #3.

5AM Venture Management first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $76.2M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

5AM Venture Management held 4,056,379 shares of Entrada Therapeutics worth $29.9M as of Q2 2026.
5AM Venture Management left its Entrada Therapeutics share count unchanged in Q2 2026.
Entrada Therapeutics made up 10.37% of 5AM Venture Management's portfolio in Q2 2026, its #3 holding.
5AM Venture Management first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
5AM Venture Management's Entrada Therapeutics position peaked at $76.2M in Q4 2024.
129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on 5AM Venture Management's 13F filing for Q2 2026, filed 14 Aug 2026.